Arcus Biosciences Quarterly Balance Sheet
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcus Biosciences financial position
As of Jun 30, 2026, Arcus Biosciences reported total assets of $924.0 million, down 14.0% from a year earlier against total liabilities of $460.0 million. Shareholders' equity stood at $464.0 million, or 50.2% of assets. The company held $150.0 million in cash and equivalents against $101.0 million of debt, a net cash position of $49.0 million.
The current ratio (current assets divided by current liabilities) was 3.82, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.22.
Summary generated from market data by MetaCap's automated system. Methodology
Arcus Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 150.00M | 201.00M | 222.00M | 238.00M | 248.00M | 192.00M | 150.00M | 201.00M | 156.00M | 185.00M | 127.00M | 184.00M |
| Short-Term Investments | 552.00M | 621.00M | 759.00M | 593.00M | 663.00M | 805.00M | 828.00M | 888.00M | 813.00M | 810.00M | 632.00M | 615.00M |
| Total Current Assets | 756.00M | 844.00M | 1.01B | 857.00M | 946.00M | 1.03B | 1.02B | 1.13B | 1.02B | 1.06B | 831.00M | 882.00M |
| Property, Plant & Equipment | 36.00M | 38.00M | 40.00M | 42.00M | 44.00M | 46.00M | 47.00M | 48.00M | 49.00M | 51.00M | 51.00M | 50.00M |
| Long-Term Investments | 73.00M | 54.00M | 29.00M | 10.00M | 16.00M | 8.00M | 14.00M | 2.00M | 40.00M | 100.00M | 107.00M | 151.00M |
| Total Assets | 924.00M | 997.00M | 1.14B | 974.00M | 1.07B | 1.16B | 1.15B | 1.25B | 1.19B | 1.29B | 1.09B | 1.19B |
| Accounts Payable | 34.00M | 39.00M | 42.00M | 42.00M | 29.00M | 22.00M | 18.00M | 13.00M | 15.00M | 16.00M | 17.00M | 17.00M |
| Total Current Liabilities | 198.00M | 209.00M | 231.00M | 235.00M | 210.00M | 192.00M | 226.00M | 215.00M | 199.00M | 204.00M | 184.00M | 200.00M |
| Long-Term Debt | 101.00M | 100.00M | 99.00M | 98.00M | 97.00M | 48.00M | 48.00M | 47.00M | — | — | 0 | — |
| Total Liabilities | 460.00M | 473.00M | 508.00M | 538.00M | 526.00M | 625.00M | 665.00M | 687.00M | 551.00M | 586.00M | 633.00M | 671.00M |
| Shareholders' Equity | 464.00M | 524.00M | 631.00M | 436.00M | 549.00M | 531.00M | 485.00M | 565.00M | 635.00M | 707.00M | 462.00M | 520.00M |
| Retained Earnings | -1.70B | -1.61B | -1.49B | -1.38B | -1.24B | -1.24B | -1.13B | -1.04B | -946.00M | -853.00M | -849.00M | -768.00M |
| Total Debt | 101.00M | 100.00M | 99.00M | 98.00M | 97.00M | 48.00M | 48.00M | 47.00M | — | — | 0 | — |
| Net Cash (Debt) | 601.00M | 722.00M | 882.00M | 733.00M | 814.00M | 949.00M | 930.00M | 1.04B | 969.00M | 995.00M | 759.00M | 799.00M |
| Shares Outstanding | 127.00M | 125.50M | 125.30M | 107.10M | 106.40M | 105.90M | 92.20M | 91.50M | 91.30M | 90.90M | 75.50M | 74.80M |
This table shows 12 quarterly periods of Arcus Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow RCUS's reporting calendar. What is a balance sheet?